Dimerix, a clinical-stage biopharmaceutical company developing kidney disease treatments, recently announced that it had acquired DMX-652 from Mission Therapeutics. The acquisition adds a Phase II-ready acute kidney injury (AKI) programme with a differentiated mechanism, expanding Dimerix beyond its late-stage focal segmental glomerulosclerosis (FSGS) asset.
Dimerix already has a late-stage rare kidney disease asset in FSGS, so adding DMX-652 creates a continuum from acute injury to chronic disease, potentially giving the company more relevance to nephrologists, hospitals, and trial networks that span both settings. If the drug shows benefit in preventing AKI or improving recovery, it could also influence how the field thinks about interventions earlier in the kidney injury cascade rather than waiting for irreversible chronic decline. This is significant in the kidney disease space because AKI still has no approved disease-modifying therapy.
DMX-652 is an oral USP30 inhibitor designed to improve mitochondrial quality control by promoting removal of damaged mitochondria. This is relevant in AKI because mitochondrial dysfunction is implicated in tubular injury, fibrosis, and incomplete renal recovery. The available early data cited in the acquisition reports suggest it already has supportive Phase I safety and an open US investigational new drug (IND) / Phase II-ready status, which lowers clinical execution risk compared with a completely preclinical asset.
Kidney disease remains a high-unmet-need area with a large patient population, but many segments still lack strong disease-modifying options, which makes differentiated assets attractive acquisition targets. In Dimerix’s case, DMX-652 complements DMX-200 in FSGS and extends the company’s footprint across the kidney disease continuum from acute injury to chronic disease. According to GlobalData’s Drugs Database, Dimerix has four drugs in active development: propagermanium, DMX-652, DMX-700, and DMX-XXX for multiple indications. Overall, the acquisition strengthens Dimerix’s kidney disease footprint and gives the company a broader development platform across acute and chronic settings.
